Magrolimab

DB16225Investigational

Magrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).

Mechanism: Magrolimab targets the human cell surface antigen CD47.
Curator reviewed · 3 references
Also known as: 5F9 · Anti-cd47 monoclonal antibody hu5f9-g4 · Immunoglobulin g4-kappa, anti-(homo sapiens cd47 (integrin associated protein, iap, mer6, oa3)), monoclonal antibodygamma4 heavy chain (1-444) (vh (homo sapiens ighv1-3*01 (87.8%)-(ighd)-ighj4*01 (100%)) (8.8.10) (1-117)-homo sapiens ighg4*01 (ch1 (118-2 · Immunoglobulin g4(225-proline), anti-(human cd47 antigen) (human-mus musculus monoclonal hu5f9-g4 .gamma.4-chain), disulfide with human-mus musculus monoclonal hu5f9-g4 .kappa.-chain, dimer
Code names: Hu5F9 · Hu5F9-G4 · ONO-7913

Resolves to

Compound

UNII90YIEHRFJ9CAS2169232-81-7

Targets

Q08722CD47

What you can answer from here — as of May 26, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

420Drug interactionsStructured to mechanism, not free text

33Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Magrolimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account